Mitochondrial Mutations in tRNA\textsubscript{Glu} and Cytochrome b Genes Associated with Iranian Congenital Heart Disease

Mehri Khatami 1*, Mohammad Mehdi Heidari 1, Nafiseh Karimian 1, Mehdi Hadadzadeh 2

1 Department of Biology, Faculty of Science, Yazd University, Yazd, IR Iran
2 Department of Cardiac Surgery, Afshar Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran

ABSTRACT

Background: Distribution of mitochondrial oxidative energy metabolism is a characteristic of cardiomyocyte dysfunction and congenital familial and sporadic heart diseases. Several studies have indicated that mutations in mitochondrial DNA, particularly in tRNAs and MT-CYB coding for cytochrome B in complex III (CIII), were associated with cardiologic disorders. We hypothesized that mutations in these positions might play an important causal or modifying role in congenital heart defects. Congenital Heart Diseases (CHDs) are the most common anomaly in newborns and the leading non-infectious cause of mortality in the first year of life. These defects are multifactorial complex diseases resulting from both genetic predisposition and environmental risk factors. Despite advances in molecular medicine, the genetic mechanism underlying mitochondrial genetic determinants of development of CHD has remained poorly understood.

Objectives: The present study aimed to identify the association between mitochondrial mutations in tRNA\textsubscript{Glu} and Cytb genes and CHD in Iranian patients.

Materials and Methods: In this case-control study, tRNA\textsubscript{Glu} and MT-CYB genes were analyzed in DNA isolated from peripheral blood of 84 Iranian pediatric patients with non-familial CHD and 72 controls for alterations. The cases and healthy controls were matched regarding age and gender.

Results: A total of three nucleotide variations were detected by Polymerase Chain Reaction-Single-Strand Conformation Polymorphism (PCR-SSCP) and sequencing. One of them was located in tRNA\textsubscript{Glu} (A14696T) found in a child with tetralogy of fallot and ventricular septal defect, which was assessed as a pathogen mutation. The second mutation was a homoplasmic variant (m.14766C > T) in cytb gene and was not detected in the healthy controls. This variant altered an amino acid (T7I) with moderately interspecific amino acid conservation indicative of the functional importance of the residue. Finally, a homoplasmic synonymous variation (T14783C) was observed in 70.4% of the CHD patients.

Conclusions: The results suggested that mitochondrial mutations might be associated with CHD in Iranian pediatric patients. Thus, more patients with CHD should be examined for mutations in mtDNA in order to clarify the role of variants.

*Corresponding author: Mehri Khatami, Department of Biology, Faculty of Science, Yazd University, Yazd, Iran. Tel: +98-3531233013, Fax: +98-3538210644, E-mail: m.khatami@yazd.ac.ir

I. Background

Despite advances in preventive and medical care strategies, the etiology of Congenital Heart Diseases (CHDs) is not completely understood yet (1). CHD affects the structure and function of the heart in approximately 1% of all live births and can occur through a heterogeneous and complex process. Besides, it can be caused by several genes
2. Objectives
The present study also aims to identify the association between rs4977574 polymorphism in ANIRL gene and CAD incidence in a population of Iranian patients.

3. Materials and Methods
3.1. Patients
This case-control study was performed on 84 unrelated pediatric patients with congenital heart malformations selected from 112 cases referred to the Department of Cardiac Surgery in Afshar hospital (Yazd, Iran) from 2013 to 2015. All the samples were obtained from the CHD patients undergoing cardiac surgery at Afshar cardiac hospital and were assessed by clinical history, physical examination, 12-lead electrocardiogram, and echocardiography. Also, 72 unrelated healthy individuals (24 males and 38 females) who were matched with the patients regarding age, sex, and ethnicity and had no family history of CHD were enrolled into the control group. In the patients group, 52 subjects (61.90%) had VSD, 20 (23.8%) suffered from ASD, and 12 (14.28%) had TOF. Besides, 63 participants were female (75%) and 21 were male (25%). Additionally, their median age at the time of surgery was 2.8 years (range 0-3.5 years). Recruitment of the patients and laboratory protocols in this study were approved by the Ethics Committee of Yazd University. After obtaining written informed consents, a 5 mL peripheral blood sample was collected from each patient. Then, genomic DNA was extracted from blood leukocytes using DNA isolation kit (Qiagene Co, Tehran, Iran).

3.2. Mutation Screening of MT-CYB
By using two pairs of specific primers designed from the genomic sequence of the mitochondrial MT-CYB gene (14747 - 15887), the two coding segments of the MT-CYB gene (initial and terminal segments) were amplified by Polymerase Chain Reaction (PCR) (Table 1). The primers were designed by primer design software (Primer Premier 5.0; Premier Biosoft Inc., Canada) and their secondary structure was examined using Gene Runner, version 3.05 (Hastings Software Inc. Hastings, NY, USA, http://www.generunner.com).PCR was performed in a 25 µL mixture containing 1xPCR buffer, 25 ng genomic DNA, 10 pmol/each forward and reverse primers, 1.5 mmol/L MgCl2, 0.2 mmol/L in each dNTPs, and 1 U Taq DNA polymerase. The amplification program included one cycle of an initial denaturation step at 94 °C for 5 min followed by 35 cycles at 94 °C for 35 sec, 57 °C for 45 sec, 72 °C for 50 sec, and a final extension at 72 °C for 10 min. The amplified products were then analyzed for size on 1.5% agarose gel. For mutation screening, Single-Strand Conformation Polymorphism (SSCP) analysis was performed in all the

<table>
<thead>
<tr>
<th>Table 1. The Primers Used for Amplification by PCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primer pairs 1</td>
</tr>
<tr>
<td>Forward 1</td>
</tr>
<tr>
<td>Reverse 1</td>
</tr>
<tr>
<td>Primer pairs 2</td>
</tr>
<tr>
<td>Forward 2</td>
</tr>
<tr>
<td>Reverse 2</td>
</tr>
</tbody>
</table>
patients and controls. For SSCP assay, the PCR products were heat-denatured at 93 °C for 3 min, chilled on ice for 3 min, and loaded onto a polyacrylamide/TBE 0.5x gel. SSCP was carried out using Payapajoohesh vertical gel. The gel concentrations and running conditions were as follows: 8% polyacrylamide gel, 16 h, room temperature, 200 V. After the run, the gel was removed from the apparatus and the DNA bands were visualized through silver staining. The typical gene variants got sequenced from a commercial agency (Macrogen Seoul, South Korea). In addition, the online multiple sequence alignment software, ClustalW2 (http://www.ebi.ac.uk/tools/msa/clustalw2/) and Blast analysis were used to determine the homology of the sequences obtained in the study and all other sequences of other species.

3.3. Software and Databases

In this study, PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) was utilized for prediction of the functional consequences of mutations and damaging effect of missense mutations on protein sequence. Besides, sequence alignment was performed using the Standard Protein Blast (blastp) program available at the National Center for Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov/Blastp) and the ClustalW program (http://bioinfo.hku.hk/services/analyseq/cgi-bin/clustalw_in.pl). Mamit-tRNA (http://mamit-trna.u-strasbg.fr) was also used for detection of the structural features of mammalian mitochondrial tRNAs and human diseases linked to point mutations in mitochondrial tRNA genes. Finally, in order to identify the hydrophobicity or hydrophilicity scales in proteins, degree of protein hydrophobicity was analyzed using a plot created by the ExPASy Protscal tool (http://web.expasy.org/protscal).

3.4. Statistical Analysis

Fisher’s exact test was used to determine the associated between mitochondrial polymorphisms and the genetic risk of CHD. The statistical analyses were performed using the GraphPad Prism software (GraphPad Software, Inc. USA) and P < 0.05 was considered to be statistically significant.

4. Results

Mutation analysis in tRNA\textsubscript{Glu} and MT-CYB genes was performed using PCR-SSCP in a total of 84 unrelated Iranian pediatric CHD patients and 72 healthy subjects. According to the results, one mutation was located in tRNA\textsubscript{Glu} (A14696T) (Figure 1). This homoplasmic mutation was found in three children with TOF and VSD and occurred at the position that was highly evolutionarily conserved nucleotide of the corresponding tRNA (Figure 2). The results of Mamit tRNA site also showed that the position of A14696T mutation was T-stem and was previously reported as a pathogenic variation in progressive encephalomyopathy (16). This mutation has not been previously reported in various CHDs and was absent among the 72 unrelated Iranian controls. The second mutation was a homoplasmic non-synonymous one (m.14766C > T) within MT-CYB gene in 12 CHD patients (6 female children with TOF, 5 with VSD, and 1 male child with ASD), but not in the healthy controls (Figure 3). C to T transition at nucleotide 66 resulted in substitution of polar threonine with non-polar isoleucine at amino acid position 7. This alteration in amino acid might impair the enzymatic function of the proteins.

**Figure 1.** Sequence Analysis of the mtDNA of the Normal Control (a) and Patient (b) Revealed the Homoplasmic Mutation of an A to G at Position 14696 in tRNA\textsubscript{Glu} Gene in a Child with Tetralogy of Fallot and Ventricular Septal Defect. SSCP Results (c)

Lines 1, 2 and 3 show shift band in patients with mutation. Lines 4, 5 and 6 show patients without any variations and line 7 is control sample.
Cytochrome b protein because of changes in the hydropathy determinants of the protein (hydropathy score was -0.7 for polar threonine but 4.5 for isoleucine) (Figure 4). The results of SSCP analysis also showed that this mutation was homoplasmic and, consequently, it was considered for pathogenicity. Accordingly, three of them (T14783C) were homoplasmic synonymous mutations observed in 70.4% of our CHD patients (60 pediatric patients) and were considered to be neutral polymorphisms based on the previous reports (17, 18).

5. Discussion

MT-CYB plays a key role in the structure of mitochondria and is one of the 11 components of complex III in oxidative phosphorylation. Cytochrome b is the only mitochondrial DNA (mtDNA) encoding the subunit of respiratory Complex III. It catalyzes the transfer of electrons from ubiquinol to Cytochrome c and utilizes the energy to translocate protons from inside to outside the mitochondrial inner membrane (15, 19). Mitochondrial Cytb is a hydrophobic and highly conserved protein containing several transmembrane domains and heme groups and has a fundamental role in ATP production. Most MT-CYB gene mutations that cause mitochondrial complex III deficiency change single protein building blocks (amino acids) in the Cytochrome b protein or lead to an abnormally short protein. These Cytochrome b alterations impair the formation of complex III, severely reducing the complex’s activity and oxidative phosphorylation. It is thought that the tissues that require a lot of energy, such as those in the muscles, brain, heart, liver, and kidneys, are most affected by reduction in oxidative phosphorylation. Damage to these tissues and organs leads to various features of mitochondrial complex III deficiency (20). Little information is presently available concerning mitochondrial respiratory and oxidative phosphorylation function in the congenital heart defects. The present study was the first molecular genetic analysis in tRNA^Glu and MT-CYB genes mutations identified in the patients with CHD. Although these heart defects might be due to diverse etiologic factors, the presence of abnormal mitochondria in our present findings suggests that defects in mtDNA should be considered in patients with these disorders. Because heart tissue was not available for our molecular genetic analysis, the mutations of this region were investigated.
in the peripheral blood. According to the results, the C14766T mutation was considered to be pathogenic because it was never reported as a neutral polymorphism despite sequencing of the cyt b gene in normal individuals. Besides, C14766T mutation resulted in replacement of polar threonine with non-polar isoleucine at amino acid position 7 (T7I). Moreover, because this position has to be functional for proton transfer to occur, the C14766T mutation is likely to inhibit proton transfer and to result in a partial block of the respiratory chain at complex III. We suggested that these mutations were responsible for decreased complex III activity and might play a role in the pathophysiology of CHD. The findings of the current study revealed a mtSNP (T14783C), which was not previously reported in any cardiac disorders. The rate of this synonymous substitution was significantly higher in the CHD patients compared to the controls (P = 0.0017). Here, we reported three children with TOF, VSD, and a previously described A-to-G mutation at nucleotide position 96 in the gene encoding tRNA glutamic acid (tRNA\textsubscript{Glu}). This base pair is in the T-stem of the tRNA predicted cloverleaf and was conserved among species. It is often difficult to distinguish pathogenic mtDNA mutations from neutral polymorphisms, especially when they occur within tRNA genes, because they do not produce alterations in polypeptide sequences. The alteration of secondary structure of this tRNA by this mtDNA mutation may lead to a failure in tRNA metabolism, thereby causing impairment of mitochondrial protein synthesis. Therefore, this mtDNA mutation may have a potential modifier role in increasing the severity of symptoms in Iranian pediatric patients with CHD. In conclusion, the current study revealed three homoplasmic mutations in mitochondrial tRNA\textsubscript{Glu} and cyt b genes in pediatric patients with congenital heart defects. These mutations were associated with the severity of heart defects in our patients, but not in the controls. This suggests the importance of mitochondrial modifier genes associated with environmental factors and responsible nuclear genes in development and evolution of the embryonic heart. Overall, the study findings demonstrated that defects in mtDNA should be considered in patients with CHDs. However, the small sample size of this study does not allow establishment of such a correlation. Thus, additional studies are required to identify the mechanisms by which these mutations affect cardiac development.

Acknowledgements

The authors would like to thank all the patients for providing blood samples for this scientific research. They are also grateful for Afshar hospital (Yazd, Iran) for their cooperation and support.

Authors’ Contribution

Study concept and design: Mehri Khatami; Acquisition of data: Mehdi Hadadzadeh, Nafiseh Karimian; Analysis and interpretation of data: Mehri Khatami; Drafting of the manuscript: Mehri Khatami, Mohammad Mehdi Heidari; Critical revision of the manuscript for important intellectual content: Mehri Khatami; Statistical analysis: Mohammad Mehdi Heidari; Administrative, technical, and material support: Mohammad Mehdi Heidari, Mehdi Hadadzadeh, Nafiseh Karimian; Study supervision: Mehri Khatami, Mohammad Mehdi Heidari

Funding/Support

The funding organization was Yazd University, which had no role in the design and conduct of the study, collection, management, and analysis of the data, and preparation, review, and approval of the manuscript.

Financial Disclosure

The authors declare that they have no conflict of interests.

References


